Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Outcomes and prognosis news

Show

From To
Smoking more harmful than HIV for people taking effective treatment, US study suggests

Smoking has the potential to shorten the life of a person taking HIV treatment by an average of six years, and is far more harmful to

Published
08 November 2016
By
Keith Alcorn
Smoking may shorten the lifespan of people living with HIV more than HIV itself

Smoking may shorten the lifespan of people living with HIV more than HIV itselfEurekAlert (press release)A new study led by researchers at Massachusetts General Hospital (MGH) finds that cigarette smoking substantially reduces the lifespan of people living with HIV in the U.S., potentially even more than HIV itself.

Published
03 November 2016
From
EurekAlert (press release)
The benefit of treatment has outweighed the clinical impact of lipodystrophy, conference hears

The 2016 International Congress on Drug Therapy in HIV Infection (HIV Glasgow) heard today that over a 20-year period, people who suffered lipodystrophy (fat redistribution) and

Published
26 October 2016
By
Gus Cairns
Educational attainment associated with health outcomes after starting HIV therapy

People with HIV who have lower educational attainment have poorer outcomes after starting combination antiretroviral therapy (cART), according to data from a large European cohort collaboration published

Published
11 October 2016
By
Michael Carter
Spanish study gives reassurance: small HIV blips do not predict treatment failure

A very low viral load (20-49 copies/ml) during HIV therapy does not increase the risk of the subsequent virological failure of treatment (viral load above 200 copies/ml), according

Published
21 September 2016
By
Michael Carter
Life expectancy of people starting HIV therapy differs sharply between high- and middle/low-income countries

There are significant disparities in the life expectancy of HIV-positive people starting combination antiretroviral therapy (cART) between world regions, according to the results of a meta-analysis published in

Published
08 September 2016
By
Michael Carter
Package of prophylaxis against infections reduces the risk of death for people starting HIV treatment very late

A package of enhanced prophylaxis against infections significantly reduced the risk of death in adults and children with advanced HIV disease after starting antiretroviral treatment in a

Published
08 August 2016
By
Keith Alcorn
Atripla three times weekly maintains HIV viral suppression for 24 weeks

People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression

Published
05 July 2016
By
Liz Highleyman
Less frequent CD4 and viral load monitoring safe for people doing well on ART

The frequency of routine monitoring for people treated with antiretrovirals with viral suppression can be safely reduced from every three months, to every six months, investigators from

Published
13 June 2016
By
Michael Carter
Big increases in proportion of HIV-positive people in US treated with ART and with viral suppression

The proportion of people living with HIV receiving care in the United States who accessed antiretroviral therapy (ART) and achieved viral suppression increased substantially between 2009 and

Published
10 June 2016
By
Michael Carter
← First12345...33Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.